Developing a new drug often means a long process of trial and error, working for years in the lab, and conducting multiple clinical trials, to get the right results. CytoReason wants to change that. The Israeli tech company creates AI-based computational disease models. With its extensive database of public and proprietary data, the company maps human diseases, tissue by tissue and cell by cell. Through its AI-led platform, CytoReason aims to help pharma companies shorten clinical trials and reduce the high costs of drug development. It's a mission that Yoav Aharoni, VP, R&D at CytoReason, was eager to be a part of. "Once I heard what CytoReason was working on, I knew that I had to be a part of it. I called them and said, 'I want in. How do I join?'"

CytoReason offers its customers a proven scientific process to gain insights and answer biological questions based on data. It has a team of scientists and data engineers who leverage the company's AI platform to pick apart and analyze huge amounts of data and get the insights that matter. For example, CytoReason has recently been working with one of its clients, Sanofi, on inflammatory bowel disease (IBD), using machine learning to help identify patient subtypes and pair them with personalized IBD targets. CytoReason's work is attracting other big pharmaceutical companies too, such as Pfizer, which wants to streamline its R&D costs, while making sure it stays on the cutting edge of AI.

"There's only so much data that humans can manually process to get the best insights. We're trying to close this gap between available data and insightful data that helps you make decisions," said Aharoni. "With Google Cloud, our teams can manage enormous amounts of data and analyze it to obtain valuable insights."